Jasmina Mallet, Clément Dondé, Caroline Dubertret, Philip Gorwood
{"title":"对于接受长效抗精神病药物治疗的精神分裂症患者而言,患者的康复意识在更大程度上介导了临床缓解与功能缓解之间的联系。","authors":"Jasmina Mallet, Clément Dondé, Caroline Dubertret, Philip Gorwood","doi":"10.1177/20451253241231269","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Clinical remission is a step towards functional remission for subjects with schizophrenia. While recovery is both a subjective personal journey and a clinical outcome to be targeted, data on patient self-rated outcomes are scarce.</p><p><strong>Objectives: </strong>(i) To determine the extent to which the association between clinical and functional remission is mediated by the subjective experience of recovery as reported by patients <i>versus</i> their relatives or their psychiatrist and (ii) to assess differences according to treatment, specifically with oral antipsychotics only <i>versus</i> long-acting injectable antipsychotics (LAIs).</p><p><strong>Design: </strong>Clinical observational study.</p><p><strong>Methods: </strong>Community-dwelling participants with schizophrenia enrolled in the EGOFORS cohort (<i>N</i> = 198) were included. Clinical symptoms and remission were assessed using the Positive and Negative Syndrome Scale. Functional remission was assessed with the Functional Remission of General Schizophrenia Scale. Awareness of recovery was assessed with one question 'What percentage of recovery do you think you have now (from 0% - no recovery - to 100% - full recovery)?', asked of the patient, also of the patient's close relative, and the psychiatrist. We used mediation analyses, taking into account the type of pharmacological treatment.</p><p><strong>Results: </strong>Remission criteria and perceived remission measures were significantly correlated, both within and between groups (<i>r</i> > 0.330). The patient's awareness of recovery mediated the relationship between clinical remission and level of functional remission, while the level of recovery according to psychiatrists or close relatives did not. The direct effect of clinical remission on the level of functional remission became non-significant when taking into account the mediator (patients' awareness of recovery) in the group of patients with LAI (<i>t</i> = 1.5, <i>p</i> = 0.150) but not in the group of patients with other treatments (<i>t</i> = 3.1, <i>p</i> = 0.003).</p><p><strong>Conclusion: </strong>Patients with LAIs may be more efficient in reporting their level of functional remission. Higher patient awareness could be an interesting candidate to explain this. However, as the study was cross-sectional, such a proposal should be tested with a more specifically designed protocol, such as a long-term cohort.</p>","PeriodicalId":23127,"journal":{"name":"Therapeutic Advances in Psychopharmacology","volume":"14 ","pages":"20451253241231269"},"PeriodicalIF":3.4000,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874148/pdf/","citationCount":"0","resultStr":"{\"title\":\"Patients' awareness of recovery mediates the link between clinical and level of functional remission in schizophrenia to a larger extent in those treated with long-acting antipsychotics.\",\"authors\":\"Jasmina Mallet, Clément Dondé, Caroline Dubertret, Philip Gorwood\",\"doi\":\"10.1177/20451253241231269\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Clinical remission is a step towards functional remission for subjects with schizophrenia. While recovery is both a subjective personal journey and a clinical outcome to be targeted, data on patient self-rated outcomes are scarce.</p><p><strong>Objectives: </strong>(i) To determine the extent to which the association between clinical and functional remission is mediated by the subjective experience of recovery as reported by patients <i>versus</i> their relatives or their psychiatrist and (ii) to assess differences according to treatment, specifically with oral antipsychotics only <i>versus</i> long-acting injectable antipsychotics (LAIs).</p><p><strong>Design: </strong>Clinical observational study.</p><p><strong>Methods: </strong>Community-dwelling participants with schizophrenia enrolled in the EGOFORS cohort (<i>N</i> = 198) were included. Clinical symptoms and remission were assessed using the Positive and Negative Syndrome Scale. Functional remission was assessed with the Functional Remission of General Schizophrenia Scale. Awareness of recovery was assessed with one question 'What percentage of recovery do you think you have now (from 0% - no recovery - to 100% - full recovery)?', asked of the patient, also of the patient's close relative, and the psychiatrist. We used mediation analyses, taking into account the type of pharmacological treatment.</p><p><strong>Results: </strong>Remission criteria and perceived remission measures were significantly correlated, both within and between groups (<i>r</i> > 0.330). The patient's awareness of recovery mediated the relationship between clinical remission and level of functional remission, while the level of recovery according to psychiatrists or close relatives did not. The direct effect of clinical remission on the level of functional remission became non-significant when taking into account the mediator (patients' awareness of recovery) in the group of patients with LAI (<i>t</i> = 1.5, <i>p</i> = 0.150) but not in the group of patients with other treatments (<i>t</i> = 3.1, <i>p</i> = 0.003).</p><p><strong>Conclusion: </strong>Patients with LAIs may be more efficient in reporting their level of functional remission. Higher patient awareness could be an interesting candidate to explain this. However, as the study was cross-sectional, such a proposal should be tested with a more specifically designed protocol, such as a long-term cohort.</p>\",\"PeriodicalId\":23127,\"journal\":{\"name\":\"Therapeutic Advances in Psychopharmacology\",\"volume\":\"14 \",\"pages\":\"20451253241231269\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2024-02-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874148/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/20451253241231269\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20451253241231269","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
摘要
背景:临床缓解是精神分裂症患者向功能缓解迈出的一步。目的:(i) 确定临床缓解与功能缓解之间的联系在多大程度上受患者及其亲属或精神科医生报告的主观康复体验的影响;(ii) 评估不同治疗方法之间的差异,特别是仅使用口服抗精神病药物与长效注射抗精神病药物(LAIs)之间的差异:临床观察研究:方法:纳入 EGOFORS 队列中居住在社区的精神分裂症患者(N = 198)。临床症状和缓解情况使用阳性和阴性综合征量表进行评估。功能性缓解采用一般精神分裂症功能性缓解量表(Functional Remission of General Schizophrenia Scale)进行评估。康复意识通过一个问题进行评估:"您认为您现在的康复百分比是多少(从 0% - 没有康复 - 到 100% - 完全康复)?"这个问题既可以问患者,也可以问患者的近亲和精神科医生。考虑到药物治疗的类型,我们进行了中介分析:结果:无论是在组内还是在组间,缓解标准和感知缓解度量都有显著相关性(r > 0.330)。患者对康复的认识是临床缓解与功能缓解水平之间关系的中介,而精神科医生或近亲提供的康复水平则不是中介。如果考虑到中介因素(患者对康复的认识),临床缓解对功能缓解水平的直接影响在LAI患者组中不显著(t = 1.5,p = 0.150),但在接受其他治疗的患者组中不显著(t = 3.1,p = 0.003):结论:接受 LAI 治疗的患者在报告其功能缓解程度时可能更有效率。结论:接受 LAI 治疗的患者在报告其功能缓解程度时可能更有效率,患者更高的认知度可能是一个有趣的解释原因。然而,由于该研究为横断面研究,因此应通过更具体的设计方案(如长期队列)对该建议进行检验。
Patients' awareness of recovery mediates the link between clinical and level of functional remission in schizophrenia to a larger extent in those treated with long-acting antipsychotics.
Background: Clinical remission is a step towards functional remission for subjects with schizophrenia. While recovery is both a subjective personal journey and a clinical outcome to be targeted, data on patient self-rated outcomes are scarce.
Objectives: (i) To determine the extent to which the association between clinical and functional remission is mediated by the subjective experience of recovery as reported by patients versus their relatives or their psychiatrist and (ii) to assess differences according to treatment, specifically with oral antipsychotics only versus long-acting injectable antipsychotics (LAIs).
Design: Clinical observational study.
Methods: Community-dwelling participants with schizophrenia enrolled in the EGOFORS cohort (N = 198) were included. Clinical symptoms and remission were assessed using the Positive and Negative Syndrome Scale. Functional remission was assessed with the Functional Remission of General Schizophrenia Scale. Awareness of recovery was assessed with one question 'What percentage of recovery do you think you have now (from 0% - no recovery - to 100% - full recovery)?', asked of the patient, also of the patient's close relative, and the psychiatrist. We used mediation analyses, taking into account the type of pharmacological treatment.
Results: Remission criteria and perceived remission measures were significantly correlated, both within and between groups (r > 0.330). The patient's awareness of recovery mediated the relationship between clinical remission and level of functional remission, while the level of recovery according to psychiatrists or close relatives did not. The direct effect of clinical remission on the level of functional remission became non-significant when taking into account the mediator (patients' awareness of recovery) in the group of patients with LAI (t = 1.5, p = 0.150) but not in the group of patients with other treatments (t = 3.1, p = 0.003).
Conclusion: Patients with LAIs may be more efficient in reporting their level of functional remission. Higher patient awareness could be an interesting candidate to explain this. However, as the study was cross-sectional, such a proposal should be tested with a more specifically designed protocol, such as a long-term cohort.
期刊介绍:
Therapeutic Advances in Psychopharmacology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of psychopharmacology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in psychopharmacology, providing a forum in print and online for publishing the highest quality articles in this area.